Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (7) , 713-718
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antiviralsJournal of Hepatology, 2017
- Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant RecipientsNew England Journal of Medicine, 2016
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialThe Lancet Infectious Diseases, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver TransplantationClinical Gastroenterology and Hepatology, 2015
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and DasabuvirAmerican Journal of Transplantation, 2015
- An Interferon-free Antiviral Regimen for HCV after Liver TransplantationNew England Journal of Medicine, 2014
- Cholestatic hepatitis C following liver transplantation: An outcome-based histological definition, clinical predictors, and prognosisLiver Transplantation, 2012
- Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis CGastroenterology, 2005